Postoperative stereotactic radiosurgery for intracranial solitary fibrous tumors/hemangiopericytomas: A systematic review and meta-analysis

IF 1.9 4区医学 Q3 CLINICAL NEUROLOGY

Journal of Clinical Neuroscience Pub Date : 2025-05-07 DOI:10.1016/j.jocn.2025.111302

Bardia Hajikarimloo , Salem M. Tos , Ibrahim Mohammadzadeh , Mohammad Amin Habibi

{"title":"Postoperative stereotactic radiosurgery for intracranial solitary fibrous tumors/hemangiopericytomas: A systematic review and meta-analysis","authors":"Bardia Hajikarimloo , Salem M. Tos , Ibrahim Mohammadzadeh , Mohammad Amin Habibi","doi":"10.1016/j.jocn.2025.111302","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Intracranial solitary fibrous tumors (SFTs) and hemangiopericytomas (HPCs) are infrequent neoplastic lesions characterized by hypercellularity and considerable vascularization. SFT/HPCs are associated with a considerably higher likelihood of recurrence and development of metastasis. Maximal safe resection with the goal of achieving gross total resection (GTR) is the gold-standard therapeutic option; however, it is challenging due to considerable vascularization and susceptibility to intraoperative hemorrhage concurrent with adjacency to the critical neurovascular structures. SRS has been demonstrated as an efficient adjuvant treatment option for intracranial SFT/HPCs. This <em>meta</em>-analysis evaluated the efficacy and safety of postoperative SRS in intracranial SFT/HPCs.</div></div><div><h3>Methods</h3><div>On February 5, 2025, a comprehensive search of PubMed, Embase, Scopus, and Web of Science was conducted. Studies that evaluated SRS in intracranial SFT/HPCs and reported local tumor control (LTC), overall survival (OS), and progression-free survival (PFS) were included. The analysis was conducted in the R program.</div></div><div><h3>Results</h3><div>Ten studies with 228 patients and 469 SFT/HPCs were included. The <em>meta</em>-analysis showed a pooled overall LTC rate of 68 % (95 %CI: 55 %–80 %), 1-year LTC rate of 94 % (95 %CI: 90 %–97 %), and 5-year LTC rate of 60 % (95 %CI: 42 %–76 %). The <em>meta</em>-analysis revealed a pooled overall OS rate of 59 % (95 %CI: 43 %–75 %), 5-year OS rate of 85 % (95 %CI: 67 %–97 %), and 10-year OS rate of 64 % (95 %CI: 25 %–95 %). In addition, The <em>meta</em>-analysis revealed a pooled ARE rate of 6 % (95 %CI: 3 %–9 %).</div></div><div><h3>Conclusion</h3><div>Postoperative SRS is an efficient and safe adjuvant therapeutic option for intracranial SFT/HPCs. SRS has comparative results to conventional RT with lower ARE. Further prospective multicenter studies with large sample sizes are required to validate our findings.</div></div>","PeriodicalId":15487,"journal":{"name":"Journal of Clinical Neuroscience","volume":"137 ","pages":"Article 111302"},"PeriodicalIF":1.9000,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Neuroscience","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0967586825002747","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Intracranial solitary fibrous tumors (SFTs) and hemangiopericytomas (HPCs) are infrequent neoplastic lesions characterized by hypercellularity and considerable vascularization. SFT/HPCs are associated with a considerably higher likelihood of recurrence and development of metastasis. Maximal safe resection with the goal of achieving gross total resection (GTR) is the gold-standard therapeutic option; however, it is challenging due to considerable vascularization and susceptibility to intraoperative hemorrhage concurrent with adjacency to the critical neurovascular structures. SRS has been demonstrated as an efficient adjuvant treatment option for intracranial SFT/HPCs. This meta-analysis evaluated the efficacy and safety of postoperative SRS in intracranial SFT/HPCs.

Methods

On February 5, 2025, a comprehensive search of PubMed, Embase, Scopus, and Web of Science was conducted. Studies that evaluated SRS in intracranial SFT/HPCs and reported local tumor control (LTC), overall survival (OS), and progression-free survival (PFS) were included. The analysis was conducted in the R program.

Results

Ten studies with 228 patients and 469 SFT/HPCs were included. The meta-analysis showed a pooled overall LTC rate of 68 % (95 %CI: 55 %–80 %), 1-year LTC rate of 94 % (95 %CI: 90 %–97 %), and 5-year LTC rate of 60 % (95 %CI: 42 %–76 %). The meta-analysis revealed a pooled overall OS rate of 59 % (95 %CI: 43 %–75 %), 5-year OS rate of 85 % (95 %CI: 67 %–97 %), and 10-year OS rate of 64 % (95 %CI: 25 %–95 %). In addition, The meta-analysis revealed a pooled ARE rate of 6 % (95 %CI: 3 %–9 %).

Conclusion

Postoperative SRS is an efficient and safe adjuvant therapeutic option for intracranial SFT/HPCs. SRS has comparative results to conventional RT with lower ARE. Further prospective multicenter studies with large sample sizes are required to validate our findings.

查看原文本刊更多论文

术后立体定向放射治疗颅内孤立性纤维瘤/血管外皮细胞瘤：系统回顾和荟萃分析

背景：颅内孤立性纤维性肿瘤（SFTs）和血管外皮细胞瘤（HPCs）是罕见的肿瘤病变，其特征是细胞增多和大量血管化。SFT/HPCs与复发和转移的可能性相当高。最大限度的安全切除，目标是实现总切除（GTR）是金标准的治疗选择；然而，由于相当大的血管化和术中出血的易感性，同时邻近关键的神经血管结构，这是具有挑战性的。SRS已被证明是颅内SFT/HPCs的有效辅助治疗选择。本荟萃分析评估了SRS在颅内SFT/HPCs术后的疗效和安全性。方法于2025年2月5日对PubMed、Embase、Scopus、Web of Science进行综合检索。这些研究评估了颅内SFT/HPCs的SRS，并报告了局部肿瘤控制（LTC）、总生存期（OS）和无进展生存期（PFS）。分析在R程序中进行。结果纳入10项研究，228例患者，469例SFT/HPCs。荟萃分析显示，总LTC率为68% (95% CI: 55% - 80%)， 1年LTC率为94% (95% CI: 90% - 97%)， 5年LTC率为60% （95% CI: 42% - 76%）。荟萃分析显示，总生存率为59% (95% CI: 43% - 75%)， 5年生存率为85% (95% CI: 67% - 97%)， 10年生存率为64% （95% CI: 25% - 95%）。此外，荟萃分析显示合并ARE率为6% （95% CI: 3% - 9%）。结论SRS是颅内SFT/HPCs术后有效、安全的辅助治疗方法。SRS与低ARE的常规RT有比较结果。需要进一步的大样本量的前瞻性多中心研究来验证我们的发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Clinical Neuroscience 医学-临床神经学

CiteScore

4.50

自引率

0.00%

发文量

402

审稿时长

40 days

期刊介绍： This International journal, Journal of Clinical Neuroscience, publishes articles on clinical neurosurgery and neurology and the related neurosciences such as neuro-pathology, neuro-radiology, neuro-ophthalmology and neuro-physiology. The journal has a broad International perspective, and emphasises the advances occurring in Asia, the Pacific Rim region, Europe and North America. The Journal acts as a focus for publication of major clinical and laboratory research, as well as publishing solicited manuscripts on specific subjects from experts, case reports and other information of interest to clinicians working in the clinical neurosciences.